NR5A2 and cancer: For example, in TCGA-BRCA, ESR1 is altered by mutation or expression in ∼10% of tumors, whereas other NRs (eg, NR5A2/LRH-1, ESRRG, NR1I3/CAR) are more frequently altered, and only a handful of cistromic datasets exist for these receptors across all cancers.